Compare JHS & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JHS | BNR |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.9M | 126.5M |
| IPO Year | 1994 | 2019 |
| Metric | JHS | BNR |
|---|---|---|
| Price | $10.43 | $16.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.3K | ★ 65.9K |
| Earning Date | 01-01-0001 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $101.46 |
| Revenue Next Year | N/A | $14.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.36 | $6.79 |
| 52 Week High | $12.09 | $41.72 |
| Indicator | JHS | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 22.35 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $11.01 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
John Hancock Income Securities Trust is a United States-based closed-end diversified management investment company. Its main objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.